Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Magic Genomix logo — One Patient : One Treatment

Magic Genomix

One Patient : One Treatment

Founded 2023 France France 7 employees

General Information

Company Name Magic Genomix
Founded Year 2023
Location France France
Employees 7
Business Model B2B, SaaS
Revenue Model Subscription, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Magic Genomix. To contact Magic Genomix, visit magic-genomix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Magic Genomix compare?

A PDF of Magic Genomix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Magic Genomix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Magic Genomix

Magic Genomix, founded in 2023 and headquartered in France, is a promising precision oncology deeptech startup. With the slogan "One Patient : One Treatment," the company is leveraging genomic instability biomarkers to revolutionize cancer treatment and mitigate risks in drug development.

Their proprietary platform includes tools such as Magic X and Magic Tween, which convert complex clinical and multimodal data into actionable insights. Magic X is particularly noteworthy for its ability to stratify chemotherapy response into actionable categories, demonstrating strong predictive capabilities for soft tissue sarcoma and expanding into ovarian, lung, and breast cancers.

Backed by a spinout investment from INSERM in January 2023, Magic Genomix presents a well-defined strategy for regulatory approval and commercialization. The company is positioned to improve cancer patient outcomes significantly, marking a remarkable step in personalized medicine.

Business keywords: Precision Oncology, DeepTech Startup, Genomic Instability Biomarkers, Personalized Cancer Treatment, Drug Development, Clinical Data Analysis, Biopsy Data Analysis, Chemotherapy Response Prediction, Soft Tissue Sarcoma, Ovarian Cancer, Lung Cancer, Breast Cancer, Targeted Therapy, Immunotherapy, Regulatory Approval

Services & Products

Genomic data analysis
Biomarker identification and stratification
Drug response signature analysis
Patient stratification for clinical trials
Magic X software and service offerings

Target Customers

Pharmaceutical Industries Biotech Companies Healthcare Professionals Clinical Researchers

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Spinout Undisclosed 1
INSERM
01 Jan 2023

Magic Genomix Alternatives & Competitors

View All Alternatives
Magic Genomix vs
Agendia
Agendia United States

MammaPrint® + BluePrint® provides you with actionable insights throughout your patient’s breast canc...

Private Equity
209 employees
Biotechnology, Health Care
Magic Genomix vs
Incyclix Bio
Incyclix Bio United States

Regaining Cell Cycle Control

Series B
13 employees
Biotechnology, Health Care
Magic Genomix vs
Ariana Pharma
Ariana Pharma France

The leading xAI-driven drug development company

Series A
37 employees
Analytics, Data Analytics
View all alternatives

FAQ About Magic Genomix

One Patient : One Treatment
Magic Genomix was founded in 2023.
Magic Genomix is headquartered in France.
Magic Genomix has a B2B and SaaS business model. Its revenue comes from Subscription, Licensing and Service Fee.
Magic Genomix has approximately 7 employees.
Magic Genomix has completed 1 funding round.
Magic Genomix offers: Genomic data analysis, Biomarker identification and stratification, Drug response signature analysis, Patient stratification for clinical trials, Magic X software and service offerings.
Top alternatives and competitors to Magic Genomix include Agendia, Incyclix Bio, Ariana Pharma, ARIZ Precision Medicine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Magic Genomix and Agendia are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Magic Genomix, https://bouncewatch.com/company/magic-genomix, updated 13 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes